Avlar BioVentures

www.avlar.com

Avlar BioVentures Ltd was founded in 1999 by Alan Goodman and Daniel Roach and manages Avlar Fund I (£21m) and Avlar Fund II (£43m). Avlar has invested in eighteen companies across a range of sub-sectors of the bioscience industries. Ten are still private, two have been merged, three have been bought by public companies, two have been sold for cash and one is listed on the public markets.

Prior to the formation of Avlar Messrs Roach and Goodman co-founded or seed financed nine life science companies. Seven of these were listed on recognized Stock Exchanges producing highly profitable realizations. These included Acambis, Chiroscience, Core, Salix and Oxford Biomedica.

Staff

Alan Goodman, Chief Executive Over the last 18 years Alan Goodman has founded or co-founded many biotechnology and healthcare companies, including Agricultural Genetics Company, Medeva plc, Chiroscience Group plc, Peptide Therapeutics (now Acambis plc), Oxford BioMedica plc, CeNeS Pharmaceuticals plc, Core Group plc and Amura Limited. He was non-executive Chairman of Oxford BioMedica plc and is currently chairman of CeNeS Pharmaceuticals plc.

Daniel Roach, Investment Director Dr Daniel Roach came to Cambridge in 1985 to join PA Consulting Group, becoming Business Development Manager for the Biotechnology Group. In 1993, he joined Advanced Technology Management Limited (ATM), a company established by Alan Goodman which has been involved in forming and seeding nine companies, seven of which subsequently listed on Stock Exchanges - Acambis, Chiroscience, CeNeS, Core, Lidco, Oxford Biomedica and Salix. He was a co-founder of Peptide Therapeutics (now Acambis) in 1993 where he was Commercial Director, CeNeS in 1996 where he was CEO from 1997-2002, Amura in 1997 and Avlar in 1998. He is currently an investment director of Avlar, the ATM group of companies, Medical Device Innovations and Purely Proteins. He has recently been appointed Entrepreneur in Residence at the Centre for Entrepreneurial Learning and to the Greater Cambridge Partnership (GCP) Operating Board. In addition, he has been a board trustee of the Babraham Institute and Chairman of ERBI. He was one of the first students to read biochemistry at the University of Swansea and has a PhD in enzymology from Bath University, funded by Porton Down.

Catherine Prescott, Science Director Catherine Prescott attained her degree in Genetics at Nottingham University and her DPhil at Oxford University. She went on to hold Research Fellowships at the University of Kent, Brown University, the Max Planck Institute and Max Delbruck Centrum. She has held a senior research position at Antisoma Limited (now Antisoma plc), was Head of RNA Research and Assistant Director at SmithKline Beecham between 1992 and 1997 before going on to become Head of Drug Discovery for RiboTargets Limited. She has run her own business providing advisory and operational consultancy. She is a member of the Institute of Pharmaceutical innovation Advisory Board and a member of various BBSRC funding committees/panels.

Contact details

Articles relating to Avlar BioVentures

Avlar funds new firm as catalyst for Babraham life science start ups

Paradigm Therapeutics raises £7m in fourth funding round

Subscribe

 

Corporate profiles

 • Cambridge Gateway Fund

Dr Catherine Beech Director

The Cambridge Gateway Fund is a venture capital fund specialising in investments in early stage companies. From its base at the centre of one of the world's fastest growing technology clusters, Gateway commits capital across the UK, actively seeking exceptional companies with unique technology in

[Cambridge Gateway Fund's profile]

Top20 Index

Currently: 71.78

Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.